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Excessive extracellular matrix production by fibro-
blasts in response to tissue injury contributes to fi-
brotic diseases, such as idiopathic pulmonary fibrosis
(IPF). Epithelial-mesenchymal transition, involving
transition of alveolar epithelial cells (AECs) to pulmo-
nary fibroblasts, appears to be an important contrib-
utory process to lung fibrosis. Although aberrant ex-
pression of microRNAs (miRs) is involved in a variety
of pathophysiologic processes, the role of miRs in
fibrotic lung diseases is less well understood. In the
present study, we found that miR-200a, miR-200b, and
miR-200c are significantly down-regulated in the
lungs of mice with experimental lung fibrosis. Levels
of miR-200a and miR-200c were reduced in the lungs
of patients with IPF. miR-200 had greater expression
in AECs than in lung fibroblasts, and AECs from mice
with experimental pulmonary fibrosis had dimin-
ished expression of miR-200. We found that the miR-
200 family members inhibit transforming growth fac-
tor-1–induced epithelial-mesenchymal transition of
AECs. miR-200 family members can reverse the fibro-
genic activity of pulmonary fibroblasts from mice
with experimental pulmonary fibrosis and from pa-
tients with IPF. Indeed, the introduction of miR-200c
diminishes experimental pulmonary fibrosis in mice.
Thus, the miR-200 family members participate impor-
tantly in fibrotic lung diseases and suggest that restor-
ing miR-200 expression in the lungs may represent a
novel therapeutic approach in treating pulmonary
fibrotic diseases. (Am J Pathol 2012, 180:484–493; DOI:
10.1016/j.ajpath.2011.10.005)
Fibroblast activation with generation of provisional extra-
cellular matrix (ECM) is a primary tissue response to
484injury.1 Successful wound repair relies on a balance of
ECM synthesis and resolution, as well as re-epithelization
of damaged epithelial surfaces.1,2 Abnormal tissue repair
is often associated with excessive ECM production that
ultimately leads to fibrosis, including idiopathic pulmo-
nary fibrosis (IPF).1,3 ECM-producing lung fibroblasts
arise from several sources, including the following: i)
resident pulmonary fibroblasts, ii) circulating fibrocytes
that then infiltrate into the lung, and iii) alveolar epithelial
cells (AECs) through a process termed epithelial-mesen-
chymal transition (EMT).4,5
EMT is a biological process that allows an epithelial cell
to undergo multiple biochemical changes, resulting in mes-
enchymal cell features, including enhanced migratory ca-
pacity, production of ECM components, and loss of epithe-
lial cell characteristics.6,7 EMT has been an essential step
during implantation of the fertilized ovum, embryogenesis,
and organ development.6,7 However, it also appears to be
an important source of fibroblasts during repair of tissue
injury associated with pathological fibrotic processes.6,7
Transforming growth factor (TGF)-1 is a central media-
tor of lung fibrosis and can induce EMT of AECs both in vitro
and in vivo.8–15 The mechanism by which TGF-1 induces
EMT involves recruitment of several transcriptional repres-
sors, including SNAI1, SNAI2, Twist1, ZEB1, and ZEB2, to
the promoters of genes required to preserve epithelial cell
phenotypes.9 Furthermore, TGF-1 induces differentiation
of pulmonary fibroblasts into myofibroblasts that are char-
acterized by expression of smooth muscle actin (SMA)-
and elevated synthesis of ECM proteins.16,17
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AJP February 2012, Vol. 180, No. 2MicroRNAs (miRs) are noncoding small RNAs, 22
nucleotides in length, that bind to the 3= UTR of target
genes and, thereby, repress translation and/or induce deg-
radation of target gene mRNAs.18 miRs have regulated
numerous molecular and cellular processes.18 Aberrant ex-
pression of miRs is associated with initiation and progres-
sion of pathological processes, including diabetes, cancer,
and cardiovascular disease.19–22 However, the role of miRs
in TGF-1–induced EMT of AECs and in lung fibrosis is not
well characterized.23 An improved understanding of the
roles that specific miRs play in the pathogenesis of lung
fibrosis is likely to suggest important new directions for the
treatment of IPF and other interstitial lung diseases.
In the present study, we demonstrate that three miR-
200 family members, including miR-200a, miR-200b, and
miR-200c, are significantly down-regulated in the lungs of
mice with bleomycin-induced lung fibrosis. The levels of
miR-200a and miR-200c were decreased in the lungs
of patients with IPF. We found that the miR-200 family
members inhibit TGF-1–induced EMT of AECs and can
reverse the fibrogenic activity of pulmonary fibroblasts
from mice with experimental pulmonary fibrosis and from
patients with IPF. Furthermore, we found that introduction
of miR-200c diminishes experimental pulmonary fibrosis
in mice. Overall, these data suggest that miR-200 family
members play an important role in the pathogenesis of
lung fibrosis and suggest that restoring miR-200 expres-
sion in the lungs may represent a novel therapeutic ap-
proach for the treatment of pulmonary fibrotic diseases.
Materials and Methods
Experimental Pulmonary Fibrosis Model
The experimental pulmonary fibrosis model was estab-
lished, as previously described.24 The animal protocol was
approved by the University of Alabama at Birmingham In-
stitutional Animal Care and Use Committee. For miR-200
treatment, control mimics (1.5 mg/kg body weight in 40 L
of saline), control mimics plus bleomycin (1.5 mg/kg mimics
plus 1 U/kg bleomycin in 40 L of saline), miR-200c mimics
(1.5 mg/kg in 40 L of saline), or miR-200c mimics plus
bleomycin (1.5 mg/kg mimics plus 1 U/kg bleomycin in 40
L of saline) were instilled intratracheally through oropha-
ryngeal cavities. At 14 days after the treatment, the severity
of lung fibrosis was evaluated.
Reagents
Human recombinant TGF-1 was obtained from Pepro-
tech (Rocky Hill, NJ). miR mimics and inhibitors were
from Ambion (Grand Island, NY).
miR Array Analysis
miR array analysis was performed as previously de-
scribed.24 Briefly, total RNAs were isolated from mouse
lungs harvested at days 0, 7, and 14 after bleomycin
instillation (three mice per group) with the miRNAeasy
Mini Kit (Qiagen, Valencia, CA). The miR array was per-formed using the miRCURY LNA microRNA Array (Ex-
iqon, Woburn, MA). The miR profiling data were depos-
ited into Array Express (accession number E-MEXP-
2749) and are free to public access.
Isolation and Culture of Primary Mouse AECs
and Pulmonary Fibroblasts
Primary AECs were isolated from saline- and bleomycin-
treated mice, as previously described, with modifica-
tions.25 In brief, lungs were lavaged through the right
ventricle with 10 mL of sterile PBS, and tissues were
minced and digested with 0.1% collagenase, 0.005%
trypsin, and 0.04% DNase. The suspension was filtered
through 40-m nylon meshes and centrifuged at 200  g
for 10 minutes. The pellet was resuspended in modified
Eagle’s media, and negative selection for lymphocytes/
macrophages was performed by incubation on CD16/32-
and CD45-coated Petri dishes for 30 minutes at 37°C.
Negative selection for fibroblasts was performed by ad-
herence for 45 minutes on cell culture dishes.
The adherent lung fibroblasts from the previously de-
scribed procedures were cultured in modified Eagle’s
media containing 10% fetal bovine serum (FBS). The
fibroblasts at passage 2 were trypsinized, and the same
numbers of cells were plated for experiments. AECs or
lung fibroblasts from each mouse were used as an inde-
pendent line. Four to five mice were used for each con-
dition in the study.
Isolation and Culture of Primary Rat AECs
Isolation and culture of primary rat AECs were performed
essentially as previously described.26 Before being
treated with TGF-1, the cells were starved in media
containing 0.5% FBS for 24 hours.
Cell Lines
The human primary pulmonary fibroblast line, MRC-5,
and the rat ATII cell line, RLE-6TN, were obtained from
American Type Culture Collection (Manassas, VA) and
cultured according to the manufacturer’s instructions.
Human Lung Tissue
IPF and histologically normal lung tissue samples were
obtained from the NIH Lung Tissue Research Consortium
and the University of Alabama at Birmingham Tissue Pro-
curement and Cell Culture Core. The protocol was ap-
proved by the Institutional Review Board at the University
of Alabama at Birmingham.
Real-Time PCR
The assay was performed as previously described.24,27
TaqMan probes for miR-200a, miR-200b, miR-200c,
RNU48, snoRNA, and sno135 were obtained from Ap-
plied Biosystems (Carlsbad, CA). The expression of
SMA-, fibronectin (Fn), collagen 1A1, E-cadherin,
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cludens-1 (ZO-1), ZEB1, and ZEB2 was determined us-
ing the SYBR Green Master Mix kit (Roche, Indian-
apolis, IN). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as an internal control. Primer se-
quences were as follows: human Fn, 5=-GTGTTGGGAATG-
GTCGTGGGGAATG-3= (sense) and 5=-CCAATGCCAC-
GGCCATAGCAGTAGC-3= (antisense); mouse Fn, 5=-TCT-
GGGAAATGGAAAAGGGGAATGG-3= (sense) and 5=-CAC-
TGAAGCAGGTTTCCTCGGTTGT-3= (antisense); mouse
SMA-, 5=-GACGCTGAAGTATCCGATAGAACACG-3=
(sense) and 5=-CACCATCTCCAGAGTCCAGCACAAT-3=
(antisense); mouse collagen 1A1, 5=-GGAGGGCGAGTGCT-
GTGCTTT-3= (sense) and 5=-GGGACCAGGAGGACCAG-
GAAGT-3= (antisense); rat ZEB1, 5=-TTTGTCTCCCAGTCA-
GCCACCTTTA-3= (sense) and 5=-GGAATCTGTCCAGCT-
TGCATCTTTT-3= (antisense); rat ZEB2, 5=-GCAGCACTTAG-
GTGTAGGGTTAGAAGC-3= (sense) and 5=-GACCGACG-
GCTGGAATACTAGGAGA-3= (antisense); rat GAPDH, 5=-AT-
GCTGGTGCTGAGTATGTCGTGGAG-3= (sense) and 5=-TG-
AGGGAGTTGTCATATTTCTCGTGGTTC-3= (antisense);
mouse E-cadherin, 5=-GTGTGCTCACCTCTGGGCTGGAC-3=
(sense) and 5=-GAGTGTTGGGGGCATCATCATCG-3= (anti-
sense); mouse GAPDH, 5=-CGACTTCAACAGCAACTC-
CCACTCTTCC-3= (sense) and 5=-TGGGTGGTCCAGGG-
TTTCTTACTCCTT-3= (antisense); human GAPDH, 5=-GCT-
GGCGCTGAGTACGTCGTGGAGT-3= (sense) and 5=-CAC-
AGTCTTCTGGGTGGCAGTGATGG-3= (antisense); mouse
ZO-1, 5=-TCTGGCATCATTCGCCTTCATACA-3= (sense)
and 5=-CGCATAATTAAGACGATCAACCGC-3= (antisense);
mouse FSP1, 5=-TCCACAAATACTCAGGCAAAGAGGG-3=
(sense) and 5=-TGTTGCTGTCCAAGTTGCTCATCAC-3=
(antisense); and rat GATA3, 5=-CCATTACCACCTATCCGC-
CCTAT-3= (sense) and 5=-GCAGTTCACACACTCCCTGC-
CTT-3= (antisense).
Western Blot Analysis
Western blot analysis was performed as previously de-
scribed.28 Mouse anti-Fn antibody and rabbit anti-GAPDH
antibodies were from Santa Cruz Biotechnology (Santa
Cruz, CA). Mouse anti-SMA- was from Sigma-Aldrich
(St. Louis, MO). Mouse anti-vimentin antibody was from
Abcam (Cambridge, MA). Mouse anti-E-cadherin and
mouse anti-N-cadherin antibodies were from BD Bio-
science (Sparks, MA).
Immunofluorescence Assay
Immunofluorescence assays were performed as previously
described.28 Confocal microscopy was also performed.
Immunohistochemical Data
Immunohistochemistry (IHC) assays were performed as
previously described.24 Briefly, sections of mouse lungs (10
m thick) were prepared, deparaffinized with xylene, and
then rehydrated in water. Antigen retrieval was performed in
a pressure cooker in Tris-EDTA solution, pH 9.0. After incu-
bation in Tris-buffered saline with Tween for 10 minutes and
3% H2O2 for 10 minutes, the sections were blocked withavidin-biotin blocker and affinity-purified goat anti-mouse
IgG [heavy chain (H) and light chain (L)]. The sections were
then incubated with mouse anti--SMA (Sigma) overnight at
4°C, secondary antibody for 45 minutes, avidin–horserad-
ish peroxidase for 45 minutes, and diaminobenzidine (DAB)
chromogen, sequentially. Finally, the sections were coun-
terstained with hematoxylin.
Collagen Content Determination
The right lungs frommice were collected and homogenized
in 5 mL of 0.5 mol/L acetic acid in PBS containing 0.6%
pepsin. The extracts were rotated at 4°C overnight and
cleared by centrifugation at 17,200  g for 15 minutes.
Collagen content was measured using the Sircol Collagen
Assay kit (Biocolor Ltd, Carrickfergus, UK), according to the
manufacturer’s instructions. Collagen content is presented
as micrograms of acid-soluble collagen per right lung.
Statistical Analysis
One-way analysis of variance, followed by the Holm-
Sidak or Tukey-Kramer test, was performed for multiple
group comparisons. The Student’s t-test was used for
comparison between two groups. P  0.05 was consid-
ered significant.
Results
miR-200 Is Down-Regulated in the Lungs of
Mice with Experimental Pulmonary Fibrosis
To examine alterations of miR in pulmonary fibrosis, we
performed miR array analyses on RNA samples isolated
from lungs of mice that were given intratracheal bleomy-
cin, a well-studied pulmonary fibrosis model.29,30 We
found that several miRs demonstrate altered expression
in fibrotic mouse lungs.24 We found that miR-21, an miR
with enhanced expression in fibrotic mouse lungs, regu-
lates pulmonary fibrogenesis in response to bleomycin-
induced lung injury.24 In our effort to characterize miRs
with reduced expression in fibrotic mouse lungs, we de-
fined the role of miR-200 family members in the regulation
of pulmonary fibrosis. To confirm the alterations of miR-
200 expression in fibrotic lungs, we performed real-time
PCR analysis and found that the expression of miR-200
family members, including miR-200a, miR-200b, and
miR-200c, is time dependently decreased in murine
lungs after intratracheal injection of bleomycin (Figure 1).
These data suggest that miR-200 may play a role in the
regulation of lung fibrosis.
miR-200 Demonstrates Greater Expression
in AECs Than in Lung Fibroblasts and Is
Down-Regulated in AECs Isolated from Fibrotic
Mouse Lungs
The AECs and lung fibroblasts are the most relevant cell
populations involved in pulmonary fibrosis. To determine
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isolated AECs and lung fibroblasts from control untreated
mice and from mice after bleomycin administration. We
found that the expression of miR-200 is down-regulated
Figure 1. miR-200 is down-regulated in the lungs of mice with experimental
pulmonary fibrosis. Mice were injected intratracheally with saline or bleo-
mycin (BLM; 1 U/kg in 50 L of saline) and sacrificed at days 0, 1, 3, 4, 7, 14,
or 24 after injection. Total RNA from the lungs was isolated, and the levels of
miR-200a, miR-200b, and miR-200c were determined by real-time PCR assays.
A small nucleolar RNA, snoRNA 135, was used as an internal control (n  3
mice in each group). Data are given as mean SD. *P 0.05, **P 0.01, and
***P  0.001 versus day 0.in the AECs isolated from mice with experimental lung
fibrosis (Figure 2A). Furthermore, we found that miR-200
is expressed in the AECs at remarkably higher levels than
in the lung fibroblasts (Figure 2B). These data suggest
that the diminished levels of miR-200 in the fibrotic lungs
are primarily derived from the decrease in the expression
of miR-200 in AECs. The AECs demonstrated much
greater expression of E-cadherin and ZO-1 (two epithelial
cell markers), whereas they demonstrated decreased
amounts of Fn and FSP1 (two fibroblast markers), than
did lung fibroblasts. These data indicate the purity of the
studied cell populations (Figure 2C). Because AECs un-
dergoing EMT are a major source of lung fibroblasts that
produce excessive ECM in fibrotic lungs, the diminished
expression of miR-200 in AECs suggests that miR-200
may participate in the regulation of EMT involving AECs
during lung fibrosis.
miR-200 Is Down-Regulated in the Lungs of
Patients with IPF
To determine whether the expression of miR-200 family
members is altered in the lungs of patients with IPF, we
measured the levels of miR-200 in control normal human
lung tissue and in the lungs of patients with IPF. As shown
in Figure 3A, the levels of miR-200a and miR-200c were
significantly decreased in the lungs of patients with IPF
compared with those in the healthy controls, although miR-
200b demonstrated a slight increase in the lungs of patients
with IPF. The expression of two ECM proteins, collagen 1A1
and Fn, was increased in the lungs of patients with IPF
(Figure 3B), consistent with previous studies.25,31
Figure 2. miR-200 demonstrates greater expres-
sion in AECs than in lung fibroblasts and is
down-regulated in AECs isolated from fibrotic
mouse lungs. Mice were injected intratracheally
with saline or bleomycin (BLM; 1 U/kg in 50 L
of saline) and sacrificed 14 days after the injec-
tion. AECs and pulmonary fibroblasts were iso-
lated and cultured as described in Materials and
Methods, and RNA from these cells was isolated.
A: The levels of miR-200a, miR-200b, and miR-
200c in the cells were determined by real-time
PCR. con indicates control. B: The levels of miR-
200a, miR-200b, and miR-200c in the AECs and
pulmonary fibroblasts were determined by real-
time PCR and are shown as CT relative to those
of a small nucleolar RNA, snoRNA 135, in the
same cells. C: The levels of E-cadherin, ZO-1,
FSP1, and Fn in the AECs and pulmonary fibro-
blasts were determined by real-time PCR and are
shown as CTrelative to those of GAPDH in the
same cells (n  5 mice per group). Data are
given as mean SD. ***P 0.001 versus the con
group.
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AECs
TGF-1 is one of the major mediators of pulmonary fibro-
sis and induces EMT of AECs in vitro.8–15 To investigate
whether miR-200 has a role in TGF-1–induced EMT tran-
sition, we first sought to determine whether TGF-1 reg-
ulates miR-200 expression in AECs. In these experi-
ments, the rat alveolar type II cell line, RLE-6TN, was
treated with TGF-1 for 0 to 3 days. As shown in Figure
4A, the expression of miR-200a, miR-200b, and miR-200c
was significantly decreased after TGF-1 treatment.
These findings suggest that miR-200 may play a role in
TGF-1–induced EMT of AECs.
To exclude the possibility that the diminished expres-
sion of miR-200 after TGF-1 treatment only occurs in
immortalized AEC lines, we treated rat primary alveolar
A
B
Figure 3. miR-200 is down-regulated in the lungs of patients with IPF. A:
Total RNA was isolated from histologically normal human lungs and from the
lungs of patients with IPF. The levels of miR-200a, miR-200b, and miR-200c
in the lungs were determined by real-time PCR. A small nucleolar RNA,
RNU48, was used as an internal control (n  8 for healthy controls, and n 
18 for IPF lungs). Data are given as mean  SEM. B: The expression of
collagen 1A1 (Col1A1) and Fn was determined in the same RNA samples.
*P  0.05, **P  0.01, and ***P  0.001 versus the control group.
β
A Btype II cells with TGF-1. As shown in Figure 4B, TGF-1
treatment markedly diminished miR-200 expression in the
primary rat alveolar type II cells.
miR-200 Promotes EMT in AECs
The EMT process is characterized by the loss of epithelial
cell phenotypes, such as diminished expression of E-
cadherin and ZO-1, and the acquisition of mesenchymal
cell phenotypes, such as enhanced expression of ECM
proteins, vimentin, SMA-, and N-cadherin.6,7 To study
the role of miR-200 in the EMT of AECs during pulmonary
fibrosis, we first determined the expression of E-cadherin
in the lungs of bleomycin- treated mice. As shown in
Supplemental Figure S1A (available at http://ajp.
amjpathol.org), the expression of E-cadherin in the lungs
of mice with bleomycin-induced pulmonary fibrosis is
markedly decreased compared with that in normal con-
trol lungs. More specifically, we found that the expression
of E-cadherin is significantly decreased in AECs isolated
from mice with bleomycin-induced lung fibrosis (see Sup-
plemental Figure S1B at http://ajp.amjpathol.org). In ad-
dition, the expression of Fn was significantly increased in
AECs isolated from mice with experimental lung fibrosis
(see Supplemental Figure S1B at http://ajp.amjpathol.
org). These data confirm previous findings8–15 that EMT
occurs during the development of lung fibrosis.
To determine the role of miR-200 in modulating EMT, we
transfected RLE-6TN cells with control miR mimics or mim-
ics for miR-200a, miR-200b, or miR-200c and then treated
the cells with TGF-1. As shown in Figure 5, A and C,
overexpression of miR-200, particularly miR-200b and miR-
200c, attenuated TGF-1–induced expression of the mes-
enchymal cell markers, including SMA- and vimentin, and
TGF-1–induced mesenchymal cell morphological charac-
teristics. Furthermore, we found that miR-200 enhanced
E-cadherin expression and attenuated TGF-1–repressed
E-cadherin expression (Figure 5B). Inhibition of miR-200
β
Figure 4. miR-200 is down-regulated in TGF-
1–treated AECs. A: RLE-6TN cells were starved
in media containing 0.5% FBS for 24 hours and
then treated with 10 ng/mL TGF-1 for 0, 24, 48,
or 72 hours. RNA was isolated, and the levels of
miR-200a, miR-200b, and miR-200c in the cells
were determined by real-time PCR. Experiments
were performed in triplicate. Data are given as
mean  SD. ***P  0.001 versus time 0. B: Rat
primary ATII cells were isolated and cultured as
described in Materials and Methods. The cells
were treated with 10 ng/mL TGF-1 for 0, 48, or 96
hours. RNA was isolated, and the levels of miR-
200a, miR-200b, and miR-200c in the cells were
determined by real-time PCR. Each condition con-
tained six replicates. Data are given as mean SD.
*P  0.05, **P  0.01 versus time 0.
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markers, including SMA-, vimentin, and N-cadherin in rat
AECs (Figure 6), although such effects were less striking, as
suggested by those found with miR-200 mimics. This may
be because of relatively low basal levels of miR-200s in the
rat cell line. Together, these data suggest that miR-200 has
an inhibitory role in TGF-1–induced EMT in AECs.
miR-200 Regulates the Expression of GATA3,
ZEB1, and ZEB2
miRs regulate various cellular processes by down-regulat-
β
α
β
β
α
β
C
B
A
Figure 5. Overexpression of miR-200 diminishes EMT in AECs. A and B: RLE-6TN
cells were transfected with 40 nmol/L control (con) miR mimics or mimics for
miR-200a, miR-200b, or miR-200c. Three days after the transfection, the cells were
starved in medium containing 0.5% FBS for 24 hours and then treated with 5 ng/mL
TGF-1 for 48 hours. The cells were collected, and cell extracts were prepared. The
levels of vimentin, SMA-, E-cadherin, and the loading con, GAPDH, were deter-
mined by using Western blot analysis. C: RLE-6TN cells, plated on coverslips, were
transfected and treated as in A and B. The cells were then fixed and permeabilized.
Immunofluorescence assays were performed with anti-SMA- antibody. Nuclei
were stained with DAPI. Original magnification, 40.ing the expression of their target genes. As shown in Sup-plemental Figure S2 (available at http://ajp.amjpathol.org),
transfection of miR-200 mimics significantly decreased the
mRNA levels of GATA3, ZEB1, and ZEB2, transcriptional
factors that have regulated EMT,32,33 in rat AECs. These
data suggest that the ability of miR-200 to diminish ex-
pression of GATA3, ZEB1, and ZEB2 may be a mecha-
nism by which miR-200 inhibits EMT in AECs.
miR-200 Diminishes the Fibrogenic Activity of
TGF-1 in Lung Fibroblasts
Lung fibroblasts function as effectors in pulmonary fi-
brosis by producing excessive collagen and Fn.4 The
finding that miR-200 inhibits EMT in AECs suggests
that restoration of expression of miR-200 family mem-
bers in the lungs may have potential therapeutic utility
in the treatment of pulmonary fibrosis. However, al-
though we have shown that miR-200 is primarily ex-
pressed in AECs, miR-200 mimics may be taken up by
both AECs and lung fibroblasts if they are introduced
intratracheally or systemically.
To determine whether miR-200 has a role in regulat-
ing the fibrogenic activity of lung fibroblasts, we trans-
fected primary human lung fibroblasts with control or
miR-200 mimics. As shown in Figure 7, overexpression
of miR-200, particularly miR-200b and miR-200c, mark-
edly attenuated TGF-1–induced expression of Fn and
SMA-. Given that TGF-1 is a central mediator of lung
fibrosis, these data suggest that therapies able to in-
crease miR-200 expression in the lungs may be able to
diminish TGF-1–mediated fibrogenesis and may at-
tenuate lung fibrosis.
β
α
α
Figure 6. Inhibition of miR-200 enhances EMT in AECs. RLE-6TN cells were
transfected with 40 nmol/L control (con) miR inhibitors or inhibitors to
miR-200a, miR-200b, or miR-200c. Three days after the transfection, the cells
were starved in media containing 0.5% FBS for 24 hours and then treated with
5 ng/mL TGF-1 for 48 hours. The cells were collected, and cell extracts were
prepared. The levels of vimentin, SMA-, N-cadherin, and the loading con-
trol, actin, were determined by using Western blot analysis.
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Lung Fibroblasts from Mice with Experimental
Pulmonary Fibrosis
Lung fibroblasts can differentiate into myofibroblasts that
are characterized by enhanced expression of SMA- and
elevated fibrogenic activity.4 To determine whether miR-200
participates in the regulation of this process, we isolated
lung fibroblasts from control mice or those with experimen-
tal pulmonary fibrosis. As shown in Figure 8A, lung fibro-
blasts frommice with experimental pulmonary fibrosis dem-
β
α
Figure 7. miR-200 diminishes the fibrogenic activity of TGF-1 in lung fibro-
blasts. Primary human lung fibroblasts were transfected with 40 nmol/L control
(con) miR mimics or mimics for miR-200a, miR-200b, or miR-200c. Three days
after transfection, the cells were starved in medium containing 0.1% FBS for 24
hours and then treated with 2 ng/mL TGF-1 for 48 hours. The cells were
collected, and cell extracts were prepared. The levels of Fn, SMA-, and the
loading control, GAPDH, were determined by using Western blot analysis.
α
BA
Figure 8. miR-200 attenuates the fibrogenic activity of lung fibroblasts from
lung fibroblasts from mice that were intratracheally injected with saline or b
The expression of Fn and SMA- was determined by real-time PCR assays. G
group. B: One fibroblast line from a mouse with experimental pulmonary
miR-200b, or miR-200c. Three days after the transfection, the cells were coll
PCR. Experiments were repeated with a second fibroblast line from fibrotic m
lung fibroblasts were transfected with 40 nmol/L con miR mimics or mimics for miR-2
collected and cell extracts were prepared. The levels of Fn, SMA-, and the loadingonstrated significantly enhanced expression of Fn and
SMA- compared with those from the lungs of untreated
mice. These data are consistent with previous findings and
suggest differentiation of fibroblasts into myofibroblasts in
fibrotic lungs.25,34,35 Next, we transfected control miR or
miR-200 mimics into lung fibroblasts from mice with exper-
imental pulmonary fibrosis. We found that overexpression of
miR-200, particularly miR-200b and miR-200c, significantly
diminished the expression of SMA- (Figure 8B), suggest-
ing that miR-200 can reverse the differentiation of lung fi-
broblasts into myofibroblasts.
miR-200 Attenuates the Fibrogenic Activity of
Human IPF Lung Fibroblasts
To further define the role of miR-200 in regulating the fibro-
genic activity of lung fibroblasts, we transfected control miR
and miR-200 mimics into lung fibroblasts isolated from a
patient with IPF and found that miR-200, particularly miR-
200b and miR-200c, diminished the expression of SMA-
and Fn in these cells (Figure 8C). Taken together, our data
suggest that introduction of miR-200 into lungs diminishes
EMT in AECs, thereby reducing the numbers of ECM-pro-
ducing lung fibroblasts, and also attenuates the fibrogenic
activity of lung fibroblasts and reverses the differentiation of
lung fibroblasts into myofibroblasts.
Introduction of miR-200c into Lungs Diminishes
Experimental Pulmonary Fibrosis in Mice
We previously showed that miR-200, particularly miR-
200b and miR-200c, decreases EMT in AECs and fibro-
genesis in IPF lung fibroblasts. We next determined if
introduction of miR-200 into lungs diminishes bleomycin-
α
α
C
ith experimental pulmonary fibrosis and from a patient with IPF. A: Primary
n (BLM) were isolated and, after culture, RNA from these cells was purified.
as used as an internal control (con). *P  0.05, ***P  0.001 versus the con
was transfected with 40 nmol/L con miR mimics or mimics for miR-200a,
d RNA was isolated. The expression of SMA- was determined by real-time
ngs and showed the same results. **P  0.001 versus the con group. C: IPFmice w
leomyci
APDH w
fibrosis
ected an
ouse lu00a, miR-200b, or miR-200c. Three days after the transfection, the cells were
con, GAPDH, were determined by using Western blot analysis.
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AJP February 2012, Vol. 180, No. 2induced lung fibrosis. As shown in Figure 9A, there was
significantly increased collagen deposition in the lungs of
bleomycin-instilled mice that received control mimics.
However, the enhanced collagen deposition was remark-
ably attenuated in the lungs of bleomycin-instilled mice
that received miR-200c mimics. These data suggest that
miR-200c prevents lung fibrosis. H&E staining also dem-
onstrated dramatic attenuation of bleomycin-induced
lung fibrosis in mice that received miR-200c probes; this
finding was confirmed by Masson’s trichrome staining,
which highlights collagen deposition (Figure 9, B and C).
Likewise, the introduction of miR-200c probes prevented
the accumulation of myofibroblasts in bleomycin-treated
lungs, as demonstrated by IHC staining with anti- SMA-
antibody (Figure 9D).
Discussion
miRs regulate numerous physiological and pathological
processes. However, the role of miRs in the pathogenesis
of lung fibrosis has not been well characterized.19–22 In
our previous study,24 we found that the expression of
α
B
C
D
AmiR-21 is enhanced in the lungs of mice with bleomycin-induced lung fibrosis and in the lungs of patients with IPF.
Blocking miR-21 attenuated experimental lung fibrosis.24
In another study, Pandit et al23 demonstrated that let-7d
is down-regulated in the lungs of patients with IPF. They
further provided evidence showing that let-7d is a nega-
tive regulator of pulmonary fibrosis.23 These previous
studies suggest that miRs play important roles in the
initiation and progression of lung fibrosis.
In the present study, we defined the role in pulmonary
fibrosis of members of the miR-200 family that were iden-
tified by miR array assays as showing decreased expres-
sion in fibrotic mouse lungs. Three of the miR-200 family
members, specifically miR-200a, miR-200b, and miR-
200c, were all down-regulated in the lungs of bleomycin-
treated mice. Previous studies33,36,37 had shown that
miR-200 promotes EMT in cancer cells and is involved in
cancer metastasis, in which EMT plays an important role.
We found that miR-200 demonstrated much greater
expression in AECs than in lung fibroblasts. These data
suggest that miR-200 is involved in the phenotypic ab-
normalities of AECs that accompany pulmonary fibrosis
but may not play a significant role in the production of
Figure 9. Introduction of miR-200 into lungs diminishes
bleomycin (BLM)–induced pulmonary fibrosis. A: Control
(con) mimics, con mimics plus bleomycin, miR-200c mimics,
or miR-200c mimics plus BLM were instilled intratracheally
through oropharyngeal cavities. At 14 days after the treat-
ment, collagen contents in the right lungs were determined
by Sircol assays (n  3, 9, 3, and 9, respectively). Data are
given as meanSEM. **P  0.01 versus con miR-; †P  0.01
versus con miR. B–D: The experiments were performed as
in A. Lung tissue sections were prepared, and H&E staining
(B), Masson’s trichrome staining (C), and IHC staining for
SMA- (D) were performed. Original magnification, 40.collagen and other ECM proteins by lung fibroblasts. The
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AJP February 2012, Vol. 180, No. 2important contribution of EMT of AECs to lung fibrosis has
been well documented.8–15 In the present study, we
found that the epithelial cell marker, E-cadherin, is signif-
icantly down-regulated, whereas Fn is significantly up-
regulated in AECs isolated from mice with bleomycin-
induced lung fibrosis. Our data, together with previous
studies, are consistent with the presence of EMT during
lung fibrosis and suggest that down-regulation of miR-
200 in AECs may contribute to EMT, thereby enhancing
pulmonary fibroblast accumulation and lung fibrosis.
TGF-1 plays a central role in the pathogenesis of lung
fibrosis by enhancing the fibrogenic activity of lung fibro-
blasts and inducing the differentiation of lung fibroblasts
into myofibroblasts.38–42 Furthermore, TGF-1 is a potent
inducer of EMT of AECs both in vivo and in vitro.8–15 In the
present study, we found that TGF-1 markedly down-
regulated miR-200 expression in primary rat ATII cells
and in the rat ATII cell line, RLE-6TN. These data suggest
that the miR-200 family may be a negative regulator of
TGF-1–induced EMT of AECs. Indeed, we found that
overexpression of miR-200, particularly miR-200b and
miR-200c, diminishes TGF-1–induced EMT of AECs, as
demonstrated by attenuation of TGF-1–induced expres-
sion of mesenchymal markers and preservation of the
expression of epithelial cell markers in AECs transfected
with miR-200. Conversely, we found that inhibition of miR-
200 enhances TGF-1–induced EMT of AECs. Taken to-
gether, these data suggest that miR-200 participates in
the pathogenesis of lung fibrosis by regulating TGF-1–
induced EMT in AECs.
We found that miR-200 is down-regulated in the lungs
of patients with IPF. These data are significant because
miR-200 may be a target in developing novel therapeu-
tics for the treatment of pulmonary fibrosis. A recent
study43 found increased expression of miR-200 in the
lungs of patients with interstitial lung disease, although
the authors suggested a negative regulation of pulmo-
nary fibrosis by miR-200. The discrepancy could be ex-
plained by diverse disease stages and diagnoses of the
selected patient populations. The mechanism by which
miR-200 is down-regulated in the lungs of patients with
IPF is unknown but may be a response to the enhanced
activity of TGF-1 in this setting. Although miR-200a,
miR-200b, and miR-200c are all down-regulated in the
lungs of mice with experimental pulmonary fibrosis, we
found decreased expression of miR-200a and miR-200c,
but not miR-200b, in IPF lungs. Given that the miR-200a
and miR-200b genes are located in the same genomic
locus and controlled by the same promoter, these data
suggest that the expression of miR-200b in IPF lungs is
regulated at the transcriptional level and by post-tran-
scriptional mechanisms that may be associated with
other disease conditions, such as exacerbation.
Recent studies25,34,35 have shown that pulmonary fi-
broblasts from the lungs of patients with IPF and from the
lungs of mice with experimental pulmonary fibrosis pos-
sess increased fibrogenic and proliferative properties
compared with those from normal lungs, even in the
absence of extracellular stimuli. These data suggest that
fibroblasts in fibrotic lungs have acquired an intrinsic
transition to a pathological phenotype that enables thesecells to produce excessive ECM proteins or to become
fibrogenic myofibroblasts, even without a profibrogenic
microenvironment, although the mechanism by which
these phenomena occur is unclear. Consistent with those
studies, we found that pulmonary fibroblasts from mice
with experimental lung fibrosis demonstrate significantly
enhanced expression of Fn and SMA-. However, al-
though miR-200 has minimal expression in lung fibro-
blasts, the transfection of fibroblasts from the fibrotic
mouse lungs with miR-200 resulted in significantly down-
regulated expression of SMA-. More important, trans-
fection with miR-200 of IPF fibroblasts attenuated expres-
sion of SMA- and Fn. These data suggest that miR-200
may be able to reverse the intrinsically acquired patho-
logical phenotypes of fibroblasts in the lungs of patients
with IPF. This result also implies that the introduction of
miR-200 into fibrotic lungs may blunt EMT among AECs,
thereby reducing the accumulation of ECM-producing
lung fibroblasts, and may reverse the fibrogenic pheno-
types of pulmonary fibroblasts in fibrotic lungs. Therefore,
miR-200 may produce benefit through a dual mechanism
in treating lung fibrosis. Indeed, we found that introduc-
tion of miR-200c diminishes bleomycin-induced pulmo-
nary fibrosis in mice, suggesting that restoring miR-200c
may be a novel approach for treating lung fibrosis.
Although the present data suggest that miR-200 can
attenuate and perhaps even reverse the fibrogenic activ-
ity of active pulmonary fibroblasts in fibrotic lungs, it is
possible that the mechanism for this effect of miR-200 is
distinct from the participation of miR-200 in modulating
EMT. Given that miRs usually have multiple effects
through regulating the expression of more than one target
gene, the identification of miR-200 targets may shed light
on how fibroblasts acquire autonomous fibrogenic phe-
notypes in fibrotic lungs. These questions are being in-
vestigated in our laboratory.
The administration of miR-200c diminishes bleomycin-
induced pulmonary fibrosis; however, miR mimics may
be short-lived molecules. Given the progressive nature of
human pulmonary fibrosis, miR molecules with therapeu-
tic potency require chemical modifications that have op-
timal combinations of being able to enhance the stability
and preserve the activity of miR in vivo.
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